Come join me and Wendi Lau from Abbvie as we participate in an interactive roundtable discussion on pharmaceutical portfolio management. We’ll be sharing our expertise and best practices for strategic…
When it comes to pricing generic drugs, there are a number of factors that come into play. In countries without drug price regulations, the pricing is based largely on profitability.…
Want insights into the biggest revenue-changing events? ➤ Get Your Certificate Today By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay…
How Much Time Are You Wasting on Manual, Repetitive Tasks? Stop wasting time on repetitive reports: Contact us Are your staff burdened with manual, repetitive tasks, like data collection, and…
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of excipients (inactive ingredients) in drugs, and integrated it with our…
Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on…
This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve…
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…
This article was first published by Elinevan Overbeeke, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and StevenSimoens in Drug Discovery Today under a Creative Commons License. Highlights…
This article was originally published by Abdrhman Mahmoud Gamil in World Journal of Advanced Research and Reviews, 2020, 08(03), 337–349 under a Creative Commons Attribution Liscense 4.0. Abstract Procurement is…
